nasopharyngeal cancer
Despite Overall Survival Miss, Singapore Researchers Champion Success of Global Cell Therapy Trial
Premium
The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell therapy to date.
Biosyngen to Begin Phase II Study of CAR T-Cell Therapy in EBV-Positive Nasopharyngeal Carcinoma
A Phase I trial showed that Biosyngen's EBV-specific CAR T-cell therapy BRG01 was safe and well tolerated with early signs of efficacy.
Naveris, Mayo Clinic Begin Trial of Circulating Tumor DNA Test in Head and Neck Cancer
Researchers hope to establish the ability of Naveris' NavDx test to guide treatment intensity for patients with HPV-driven head and neck cancer.
Singapore Institutions Launch Program to Diagnose, Treat EBV-Associated Nasopharyngeal Cancer
The program, funded by Singapore's National Research Foundation, aims to identify Epstein-Barr virus strains associated with NPC in Southeast Asian populations.
Naveris Nabs $33.4M Series A Round Expansion to Further Commercialize Virus-Related Cancer Tests
The new funding brings the total investment in the firm to $51 million, which Naveris will use for commercialization of its NavDx assay.
Feb 12, 2021
Jan 23, 2020